Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
159.2 EUR | +0.01% | -2.46% | -10.03% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With an expected P/E ratio at 31.45 and 28.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.03% | 78.17B | - | ||
+22.25% | 3.62B | B- | ||
-6.95% | 3.09B | B- | ||
+13.51% | 1.68B | - | ||
-5.47% | 1.3B | - | ||
-28.97% | 1.18B | B | ||
-31.03% | 1.15B | C- | ||
-21.79% | 1.02B | - | ||
-2.81% | 926M | D+ | ||
-11.53% | 925M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- ZOE Stock
- Ratings Zoetis Inc.